Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.74 | 12.38 | 14.59 | 11.73 | 13.23 | 13.47 | 11.86 | 14.20 | 11.73 | 20.97 | 13.56 | — | 10.18 | 15.94 | 21.14 | 16.04 | 8.76 | 17.27 | 18.81 | 13.25 | 13.07 |
| — | -8.1% | +23.0% | -17.4% | +12.8% | -35.8% | -12.5% | — | +15.3% | +31.6% | -35.9% | — | +16.2% | -7.7% | +12.4% | +21.0% | -32.9% | +4.9% | +147.7% | +631.6% | +1.8% | |
| P/S Ratio | 6.54 | 5.26 | 4.87 | 4.22 | 4.72 | 5.44 | 4.65 | 4.84 | 3.93 | 4.99 | 4.32 | 3.03 | 3.84 | 5.53 | 8.69 | 6.27 | 3.61 | 5.24 | 4.81 | 3.97 | 4.26 |
| — | -3.4% | +4.7% | -12.9% | +20.0% | +9.0% | +7.5% | +59.7% | +2.6% | -9.8% | -50.2% | -51.7% | +6.4% | +5.5% | +80.5% | +57.9% | -15.3% | +28.8% | +68.9% | +47.6% | +2.3% | |
| P/B Ratio | 4.20 | 3.10 | 3.11 | 2.72 | 3.23 | 3.88 | 3.62 | 3.77 | 3.17 | 3.50 | 4.93 | 3.57 | 4.07 | 5.66 | 7.03 | 5.32 | 3.18 | 4.10 | 3.57 | 2.88 | 3.28 |
| — | -20.0% | -14.1% | -27.9% | +1.9% | +10.6% | -26.5% | +5.5% | -22.1% | -38.1% | -29.9% | -32.8% | +28.1% | +38.0% | +97.1% | +84.9% | -3.1% | +49.1% | +71.1% | +42.7% | -26.1% | |
| P/FCF | 18.48 | 13.19 | 16.55 | 19.30 | 9.71 | 12.82 | 9.31 | 8.58 | 7.53 | 15.50 | 8.96 | 6.91 | 12.42 | — | 13.17 | 8.70 | 7.32 | 26.66 | 9.64 | 6.60 | 9.88 |
| — | +2.9% | +77.8% | +124.8% | +29.0% | -17.3% | +3.8% | +24.2% | -39.4% | — | -31.9% | -20.5% | +69.7% | — | +36.7% | +31.7% | -25.9% | -37.1% | +42.9% | -4.3% | +6.3% | |
| EV / EBITDA | 10.65 | 7.19 | 7.93 | 6.00 | 6.99 | 8.59 | 7.33 | 8.51 | 6.12 | 11.35 | 8.74 | — | 6.12 | 10.34 | 14.43 | 11.54 | 4.89 | 10.48 | 11.16 | 7.50 | 7.69 |
| — | -16.3% | +8.1% | -29.5% | +14.2% | -24.4% | -16.1% | — | +0.0% | +9.8% | -39.4% | — | +25.2% | -1.4% | +29.3% | +53.9% | -36.5% | +12.6% | +73.0% | +77.1% | -16.6% | |
| EV / EBIT | 12.21 | 7.09 | 7.87 | 6.39 | 7.64 | 8.77 | 7.15 | 8.98 | 6.98 | 14.27 | 9.52 | — | 7.24 | 12.25 | 13.76 | 11.80 | 4.89 | 10.50 | 11.19 | 7.52 | 7.71 |
| — | -19.2% | +10.1% | -28.8% | +9.4% | -38.5% | -24.9% | — | -3.6% | +16.4% | -30.8% | — | +48.0% | +16.7% | +23.0% | +57.0% | -36.5% | +11.7% | +72.8% | +77.0% | -16.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.2% | 83.8% | 82.9% | 82.9% | 79.6% | 87.3% | 84.7% | 85.0% | 87.4% | 87.3% | 85.7% | 86.2% | 87.9% | 88.3% | 81.6% | 83.1% | 85.6% | 86.3% | 80.8% | 85.2% | 87.5% |
| — | -4.0% | -2.2% | -2.4% | -9.0% | +0.1% | -1.1% | -1.4% | -0.5% | -1.2% | +5.1% | +3.7% | +2.7% | +2.3% | +0.9% | -2.5% | -2.2% | +2.2% | -4.1% | -1.8% | +1.7% | |
| Operating Margin | 43.8% | 49.0% | 40.5% | 44.7% | 45.2% | 44.8% | 44.3% | 39.6% | 44.2% | 27.5% | 37.7% | -36.2% | 46.9% | 41.7% | 50.7% | 43.9% | 53.8% | 40.3% | 33.3% | 38.9% | 43.6% |
| — | +9.4% | -8.5% | +12.9% | +2.3% | +62.7% | +17.5% | +209.2% | -5.7% | -34.0% | -25.6% | -182.6% | -12.8% | +3.5% | +52.4% | +12.6% | +23.5% | +24.2% | +19.7% | -2.4% | +25.4% | |
| Net Margin | 36.4% | 42.7% | 34.5% | 35.6% | 35.6% | 40.1% | 39.4% | 34.1% | 33.2% | 23.6% | 31.5% | -30.0% | 37.9% | 34.6% | 41.9% | 39.7% | 40.7% | 30.7% | 24.3% | 28.7% | 33.5% |
| — | +6.3% | -12.5% | +4.3% | +6.9% | +69.8% | +25.2% | +213.8% | -12.3% | -31.8% | -24.8% | -175.4% | -6.8% | +12.7% | +72.5% | +38.3% | +21.5% | +21.1% | -34.1% | -80.6% | +1.4% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.5% | 6.5% | 5.6% | 5.9% | 6.3% | 7.5% | 8.1% | 6.9% | 7.0% | 4.9% | 9.5% | -8.5% | 10.7% | 9.3% | 8.9% | 8.9% | 9.4% | 6.2% | 4.6% | 5.3% | 6.6% |
| — | -13.1% | -30.2% | -14.0% | -9.4% | +52.1% | -14.9% | +181.3% | -34.5% | -47.4% | +6.0% | -195.5% | +13.7% | +50.4% | +94.5% | +67.0% | +41.4% | +40.9% | -34.5% | -83.5% | -28.5% | |
| ROA | 21.9% | 5.7% | 4.9% | 5.2% | 5.5% | 6.4% | 6.9% | 5.9% | 6.0% | 4.2% | 7.9% | -7.2% | 8.9% | 7.6% | 7.2% | 7.6% | 8.4% | 5.5% | 4.0% | 4.8% | 6.0% |
| — | -12.3% | -29.1% | -12.1% | -8.1% | +54.7% | -12.7% | +182.7% | -32.0% | -44.8% | +9.8% | -194.7% | +5.5% | +38.3% | +78.0% | +58.6% | +40.2% | +38.9% | -35.2% | -83.1% | -23.6% | |
| ROIC | 83.8% | 21.6% | 19.3% | 22.6% | 23.5% | 22.1% | 21.7% | 16.7% | 16.6% | 8.0% | 12.9% | -12.9% | 18.0% | 27.4% | 193.6% | 72.2% | 53.4% | 30.4% | 21.8% | 19.8% | 20.9% |
| — | -2.1% | -11.0% | +35.7% | +41.8% | +176.1% | +68.0% | +228.9% | -7.8% | -70.8% | -93.3% | -117.9% | -66.3% | -10.1% | +787.8% | +264.0% | +155.2% | +96.6% | +33.3% | -59.4% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -32.0% | -33.3% | -36.8% | -37.0% | -37.0% | -52.2% | -52.5% | -44.2% | -45.9% | -29.3% | -29.0% | -40.9% | -39.0% | -36.2% | -31.2% | -25.3% | -21.2% | +11780.7% | +2827.2% | +1164.0% | |
| Debt / EBITDA | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.09 | 0.07 | — | 0.07 | 0.09 | 0.12 | 0.15 | 0.14 | 0.24 | 0.33 | 0.30 | 0.27 |
| — | -24.0% | -11.5% | -29.8% | -25.5% | -55.3% | -37.0% | — | -21.4% | +5.0% | -43.4% | — | -52.4% | -61.9% | -62.4% | -48.9% | -47.1% | -44.7% | +9709.8% | +3002.4% | +1287.2% | |
| Current Ratio | 6.08 | 7.10 | 6.08 | 6.62 | 6.71 | 6.14 | 5.17 | 5.11 | 5.14 | 5.09 | 2.88 | 3.32 | 4.59 | 3.51 | 5.57 | 6.18 | 10.79 | 9.64 | 7.76 | 9.35 | 10.93 |
| — | +15.6% | +17.6% | +29.5% | +30.6% | +20.8% | +79.2% | +54.0% | +12.0% | +45.0% | -48.2% | -46.3% | -57.4% | -63.6% | -28.2% | -33.9% | -1.3% | -13.8% | +10.9% | +19.0% | +68.4% | |
| Quick Ratio | 5.82 | 6.84 | 5.82 | 6.40 | 6.55 | 5.96 | 5.01 | 4.92 | 4.94 | 4.83 | 2.68 | 3.17 | 4.38 | 3.33 | 5.45 | 6.02 | 10.44 | 9.30 | 7.47 | 9.02 | 10.49 |
| — | +14.7% | +16.3% | +30.1% | +32.5% | +23.4% | +86.9% | +55.6% | +12.8% | +45.4% | -50.9% | -47.5% | -58.0% | -64.2% | -27.0% | -33.2% | -0.5% | -14.5% | +10.0% | +18.6% | +63.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -140.33 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CPRX stock.
Catalyst Pharmaceuticals, Inc.'s current P/E is 18.7x. The average P/E over the last 4 quarters is 13.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Catalyst Pharmaceuticals, Inc.'s current operating margin is 43.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Catalyst Pharmaceuticals, Inc.'s business trajectory between earnings reports.